ENCell Co

ENCell Co Liabilities

The The Liabilities of ENCell Co (456070.KQ) as of Oct 27, 2026 is 24.31 B KRW. In the previous year, The Liabilities was 7.58 B KRW — a change of 220.84% (higher).

Liabilities

24.31 BKRW

YoY

220.84%

Last updated:

In 2025, ENCell Co's total liabilities amounted to 24.31 B KRW, a 220.84% difference from the 7.58 B KRW total liabilities in the previous year.

The ENCell Co Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2021
42.20 B KRW
Jan 1, 2022
78.58 B KRW
Jan 1, 2023
5.96 B KRW
Jan 1, 2024
7.58 B KRW
Jan 1, 2025
24.31 B KRW
The ENCell Co Liabilities history
YEARLiabilitiesYoY
24.31 BKRW+220.84%
7.58 BKRW+27.03%
5.96 BKRW-92.41%
78.58 BKRW+86.21%
42.20 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ENCell Co Stock analysis

What does ENCell Co do? ENCell Co Ltd generates revenue through the development and research of cell and gene-based biopharmaceuticals, offering biopharmaceutical quality testing services, and providing biopharmaceutical consignment production. The company serves pharmaceutical and biotechnology firms requiring advanced drug development solutions and quality assurance. Its primary focus is on cell and gene therapies, with services tailored to support clients in the biopharmaceutical industry. The firm's offerings include research, testing, and production services for biopharmaceutical products. The company's core business model revolves around delivering specialized services to clients in the life sciences sector. It targets pharmaceutical companies and biotech firms seeking to develop and produce cell and gene-based treatments. ENCell's quality testing services ensure regulatory compliance and product safety, while its consignment production supports clients in scaling manufacturing without capital investment. These services collectively address key needs in the biopharmaceutical development lifecycle. ENCell Co Ltd's revenue streams are derived from research contracts, testing service fees, and consignment production agreements. The company's clients include pharmaceutical and biotechnology firms that outsource their biopharmaceutical development and production needs. By focusing on cell and gene-based therapies, ENCell positions itself as a specialized partner for clients navigating the complexities of modern biopharmaceutical innovation. ENCell Co is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing ENCell Co's Liabilities

ENCell Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating ENCell Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing ENCell Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

ENCell Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in ENCell Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about ENCell Co stock

The Liabilities of ENCell Co is 24.31 B KRW in 2025.

The Liabilities of ENCell Co changed from 7.58 B KRW to 24.31 B KRW, representing a 220.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities ENCell Co since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's ENCell Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ENCell Co

All Key Metrics — ENCell Co